DR.KELLY,
I JUST WANT TO GET STRAIT TO THE POINT. SINCE THE OVATURE WAS A FAILURE, WHERE DO WE GO FROM HERE AND WHAT WERE YOUR THOUGHTS ON THE ANNOUNCEMENT. I AM HAVING A HARD TIME UNDERSTANDING HOW PHENOXODIOL FAILED AFTER FOLLOWING THIS DRUG AND IT’S COMPANIES FOR THE SEVERAL YEARS. THANK YOU FOR YOUR TIME!
I hope that I have covered your questions in my last posting in the Musings section. As I say there, it is my firm belief that the OVATURE outcome represents of a failure of trial design, rather than of the drug per se. Saying anything else would be easy as it wouldn’t mean my having to face up to my shortcomings in the matter. But as I have said elsewhere, every major anti-cancer drug on the market today has failed at least one Phase 2 or Phase 3 study, and that is from major pharma companies and research institutions with almost endless resources and considerable expertise in the field. That reality simply reflects the vast challenges facing drug developers, particularly in a field as complex and opaque as cancer.
We thought that shifting from an intravenous dosage form to an oral form would provide an augmented anti-cancer effect. There was no expectation that such a change would negate the drug’s chemo-sensitising effect as happened. A large pharma company would see such an outcome as a valuable learning experience, and then get on with applying the lesson to its ongoing program. Novogen or MEI (whichever entity now survives as the stronger) now need to do the same with its Triphendiol and NV-128 drug programs.
June 1st, 2010 at 11:06 pm
DR.KELLY,
I JUST WANT TO GET STRAIT TO THE POINT. SINCE THE OVATURE WAS A FAILURE, WHERE DO WE GO FROM HERE AND WHAT WERE YOUR THOUGHTS ON THE ANNOUNCEMENT. I AM HAVING A HARD TIME UNDERSTANDING HOW PHENOXODIOL FAILED AFTER FOLLOWING THIS DRUG AND IT’S COMPANIES FOR THE SEVERAL YEARS. THANK YOU FOR YOUR TIME!
July 12th, 2010 at 10:03 am
David
I hope that I have covered your questions in my last posting in the Musings section. As I say there, it is my firm belief that the OVATURE outcome represents of a failure of trial design, rather than of the drug per se. Saying anything else would be easy as it wouldn’t mean my having to face up to my shortcomings in the matter. But as I have said elsewhere, every major anti-cancer drug on the market today has failed at least one Phase 2 or Phase 3 study, and that is from major pharma companies and research institutions with almost endless resources and considerable expertise in the field. That reality simply reflects the vast challenges facing drug developers, particularly in a field as complex and opaque as cancer.
We thought that shifting from an intravenous dosage form to an oral form would provide an augmented anti-cancer effect. There was no expectation that such a change would negate the drug’s chemo-sensitising effect as happened. A large pharma company would see such an outcome as a valuable learning experience, and then get on with applying the lesson to its ongoing program. Novogen or MEI (whichever entity now survives as the stronger) now need to do the same with its Triphendiol and NV-128 drug programs.
Graham Kelly